Risk of intracranial meningioma in patients with acromegaly: a systematic review.

Acromegaly is a rare endocrine disorder caused by hypersecretion of growth hormone (GH) from a pituitary adenoma. Elevated GH levels stimulate excess production of insulin-like growth factor 1 (IGF-1) which leads to the insidious onset of clinical manifestations. The most common primary central nervous system (CNS) tumors, meningiomas originate from the arachnoid layer of the meninges and are typically benign and slow-growing. Meningiomas are over twice as common in women as in men, with age-adjusted incidence (per 100,000 individuals) of 10.66 and 4.75, respectively. Several reports describe co-occurrence of meningiomas and acromegaly. We aimed to determine whether patients with acromegaly are at elevated risk for meningioma. Investigation of the literature showed that co-occurrence of a pituitary adenoma and a meningioma is a rare phenomenon, and the majority of cases involve GH-secreting adenomas. To the best of our knowledge, a systematic review examining the association between meningiomas and elevated GH levels (due to GH-secreting adenomas in acromegaly or exposure to exogenous GH) has never been conducted. The nature of the observed coexistence between acromegaly and meningioma -whether it reflects causation or mere co-association -is unclear, as is the pathophysiologic etiology. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022376998.

Mobile phone use and brain tumour risk - COSMOS, a prospective cohort study.

BACKGROUND: Each new generation of mobile phone technology has triggered discussions about potential carcinogenicity from exposure to radiofrequency electromagnetic fields (RF-EMF). Available evidence has been insufficient to conclude about long-term and heavy mobile phone use, limited by differential recall and selection bias, or crude exposure assessment. The Cohort Study on Mobile Phones and Health (COSMOS) was specifically designed to overcome these shortcomings. METHODS: We recruited participants in Denmark, Finland, the Netherlands, Sweden, and the UK 2007-2012. The baseline questionnaire assessed lifetime history of mobile phone use. Participants were followed through population-based cancer registers to identify glioma, meningioma, and acoustic neuroma cases during follow-up. Non-differential exposure misclassification was reduced by adjusting estimates of mobile phone call-time through regression calibration methods based on self-reported data and objective operator-recorded information at baseline. Hazard ratios (HR) and 95% confidence intervals (CI) for glioma, meningioma, and acoustic neuroma in relation to lifetime history of mobile phone use were estimated with Cox regression models with attained age as the underlying time-scale, adjusted for country, sex, educational level, and marital status. RESULTS: 264,574 participants accrued 1,836,479 person-years. During a median follow-up of 7.12 years, 149 glioma, 89 meningioma, and 29 incident cases of acoustic neuroma were diagnosed. The adjusted HR per 100 regression-calibrated cumulative hours of mobile phone call-time was 1.00 (95 % CI 0.98-1.02) for glioma, 1.01 (95 % CI 0.96-1.06) for meningioma, and 1.02 (95 % CI 0.99-1.06) for acoustic neuroma. For glioma, the HR for ≥ 1908 regression-calibrated cumulative hours (90th percentile cut-point) was 1.07 (95 % CI 0.62-1.86). Over 15 years of mobile phone use was not associated with an increased tumour risk; for glioma the HR was 0.97 (95 % CI 0.62-1.52). CONCLUSIONS: Our findings suggest that the cumulative amount of mobile phone use is not associated with the risk of developing glioma, meningioma, or acoustic neuroma.

Adjuvant Stereotactic Radiosurgery for Clear Cell Meningiomas.

OBJECTIVE: Clear cell meningiomas (CCM) are an uncommon meningioma subtype marked by aggressive growth and high rates of recurrence despite initial resection. The present study evaluates the adjuvant benefit of stereotactic radiosurgery (SRS) for residual or recurrent tumors. METHODS: After review of our prospectively maintained database, we identified 6 patients (3 female) with histologically confirmed Grade 2 CCMs. The median age of the patients at the time of SRS was 45 years. Five patients had undergone prior gross total surgical resection and 1 patient had subtotal resection before SRS. The median SRS treatment volume was 4.7 cc and the median radiosurgical margin dose was 13 Gy (range: 10-15 Gy). RESULTS: The median follow-up time was 35.5 months (range 6-168 months). Three patients achieved tumor control after the first SRS procedure. Three patients experienced tumor progression at 4, 22, and 32 months after initial SRS. Tumor control was obtained in 2 of these patients after additional SRS. One patient with multiple SRS procedures had suspected adverse radiation effect that was successfully treated with corticosteroids followed by bevacizumab. CONCLUSIONS: Tumor control was maintained in 5 of 6 patients after one or more SRS procedures. SRS should be considered for early intervention after surgical resection of CCM. To maximize the tumor control rate, patients with diagnosed CCM should be treated more generously and higher margin dose should be prescribed. Patients with CCM should be counselled that more than one SRS may be necessary to provide sustained tumor control.

Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.

BACKGROUND: Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. METHODS: Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940-2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. RESULTS: In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. DISCUSSION: Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.

Meningeoma pós-radioterapia / Radiation-induced meningioma

Os meningeomas são neoplasias derivadas das células aracnóideas, sendo sua origem ligada a alterações genéticas idiopáticas (deleção do braço longo do cromossomo 22), doenças predisponentes à sua formação e indução por radioterapia. Relata-se o caso de um homem de 50 anos com meningeoma pós-radioterapia diagnosticado 20 anos após o tratamento de um oligodendroglioma. Os critérios que suportam o diagnóstico de meningeoma induzido por radioterapia são discutidos, assim como é revisada a literatura pertinente ao assunto.

Meningiomas are neoplasms derived from arachnoid cells with their origin linked to idiopathic genetic abnormalities (delection of the long arm of chromosome 22), predisposing diseases and radiotherapy induction. We report the case of a 50 years-old man radiation-induced meningioma 20 years after the diagnosis, surgical and radiation treatment of an oligodendroglioma. The supporting diagnostic criteria of radiation-induced meningiomas are discussed and the pertinent literature of the theme is revised.

Meningioma del surco olfatorio / Meningioma of the olfatory sulcus

Se presenta el caso de dos pacientes con meningioma del surco olfatorio. Uno de ellos sólido y el otro quístico. Ambos pacientes del sexo masculino. Acuden a consulta por crisis convulsivas; previo al evento convulsivo, los síntomas o signos de la neoplasia pasaron desapercibidos para el paciente o sus familiares o bien no se les dio interés. Destacando la importancia de la tomografía computarizada (CT) y la resonancia magnética (MR) en el diagnóstico y en la definición de la estrategia quirúrgica

Meningiomas múltiples inducidos por radiaciones: a propósito de un caso / Multiple meningiomas induced by radiation: case report

La etiología de los meningiomas no está dilucidada. Las radiaciones son uno de los pocos factores etiológicos estudiados que pueden inducir el desarrollo de estos tumores, al provocar alteraciones en el brazo largo del cromosoma 22. Se presenta el caso de una paciente que a raíz de una osteomielitis crónica de la calota, fue irradiada en el cráneo, desarrollando 20 años más tarde múltiples meningiomas de la convexidad, que fueron resecados. Se comentan las características de los meningiomas inducidos por radiaciones, como son la multiplicidad, frecuente localización en la convexidad, tendencia a la malignización y recurrencia precoz, características que se deben tener en cuenta en el tratamiento

Incidencia de tumores cerebrales. Revisión morfológica y clasificación

Analizamos retrospectivamente la frecuencia de tumores cerebrales en el servicio de anatomía patológica del Hospital Carlos Andrade Marín en el período comprendido 1988-1994. revisamos 204 tumores primarios y secundarios diagnosticados por biopsia. Rportamos una incidencia en nuestro medio de 1.7/100.000 en hombres y 1.6/100.000 en mujeres, por debajo de lo reportado por la literatura norteamericana, cuya incidencia es de 8.2/100.000 en hombres y 8.1/100.000 en mujeres. Los tumores más frecuentemente encontrados fueron los meningiomas con un 24.01 por ciento superior a lo reportado en estudios internacionales (12 a 18 por ciento de los tumores cerebrales) astrocitomas con 20.09 por ciento. Adenomas representaron el 10.78 por ciento y los tumores metastásicos con un 8.33 por ciento similar a lo reportado en la literatura. Los tumores dependientes del tejido neuroepitelial representaron un 37,25 por ciento. La edad media fue de 36 años y la relación hombre/mujer de 1.84/1. La frecuencia de presentación de las restantes neoplasias cerebrales y su papel epidemiológico en cuanto a edad, sexo y tipo histológico concuerdan con los reportes de estadísticas mundiales...

Meningioma fibroblastico intrarraquideo cervical (C3-C4) en artritis reumatoidea

Presentamos un apaciente de 55 años de edad con diagnóstico de artritis reumatoidea (AR) clásica con una evolución de 30 años, a quien en 1989 se le diagnosticó una tumoración intrarraquídea con manifestaciones neurológicas caracterizadas por cuadriparesia e hiper-reflexia bilateral, por medio de mielo-TAC se localizó la lesion expansiva entre C3-C4, y luego se practicó laminectomía. El informe de patología fue meningioma fibroblástico. La paciente evoluciona favorablemente

Complicaciones tardías de la fractura de cráneo con lesión meníngea: presentación de tres casos clínicos / Late complications of craneal fracture with meningeal injury: presentation of 3 clinical cases

Se describen tres casos de complicación tardía de una fractura de cráneo con compromiso meníngeo: Un encefalocele orbitario con exoftalmo unilateral intermitente, una fractura crecedora de un adulto y un hundimiento craneano con rotura dural, 39, 29 y 16 años, respectivamente, después de un tratamiento craneoencefálico. Se confrontan estos casos con la literatura. Se describe el tratamiento neuroquirúrgico. Se comenta lo infrecuente de estas complicaciones tardías del traumatismo craneoencefálico